- Home
- SRV vs SRZN Comparison
SRV vs SRZN Comparison
Compare SRV & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRV | SRZN |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 180.3M | 164.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SRV | SRZN |
|---|---|---|
| Price | $39.97 | $22.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 33.9K | ★ 145.3K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 13.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,604,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.73 | $5.90 |
| 52 Week High | $44.30 | $24.94 |
Technical Indicators
Market Signals| Indicator | SRV | SRZN |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 60.38 |
| Support Level | $39.10 | $18.74 |
| Resistance Level | $40.69 | $21.26 |
| Average True Range (ATR) | 0.49 | 2.05 |
| MACD | 0.07 | 0.09 |
| Stochastic Oscillator | 60.22 | 81.00 |
Price Performance
Historical ComparisonAbout SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).